KalVista Pharmaceuticals (NASDAQ:KALV) Shares Cross Above 50 Day Moving Average – Should You Sell?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)’s stock price crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $15.52 and traded as high as $15.88. KalVista Pharmaceuticals shares last traded at $15.61, with a volume of 793,272 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on KALV shares. Needham & Company LLC increased their target price on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. HC Wainwright lifted their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Finally, TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.40.

KalVista Pharmaceuticals Stock Down 2.8%

The firm has a fifty day moving average of $15.52 and a 200-day moving average of $14.06. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The firm has a market cap of $789.09 million, a P/E ratio of -3.95 and a beta of -0.35.

Insider Buying and Selling

In related news, insider Nicole Sweeny sold 3,975 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $61,890.75. Following the completion of the transaction, the insider directly owned 47,003 shares of the company’s stock, valued at approximately $731,836.71. This trade represents a 7.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brian Piekos sold 1,767 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $27,512.19. Following the transaction, the chief financial officer owned 13,762 shares in the company, valued at approximately $214,274.34. The trade was a 11.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 33,979 shares of company stock worth $535,091. 4.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC bought a new position in shares of KalVista Pharmaceuticals in the first quarter valued at about $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in KalVista Pharmaceuticals by 13.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock valued at $281,000 after buying an additional 2,939 shares in the last quarter. Goldman Sachs Group Inc. increased its position in KalVista Pharmaceuticals by 3.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock worth $3,923,000 after buying an additional 12,263 shares during the period. Profund Advisors LLC acquired a new stake in shares of KalVista Pharmaceuticals during the second quarter worth $113,000. Finally, Nan Fung Trinity HK Ltd. bought a new stake in shares of KalVista Pharmaceuticals in the second quarter valued at about $1,747,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.